期刊文献+

酶联免疫分析检测乙型肝炎e抗原的空白限、检出限及定量限的建立与评价

Establishment and evaluation of limit of blank,limit of detection and limit of quantitation for detection of HBeAg by enzyme-linked immunosorbent assay
下载PDF
导出
摘要 目的建立并评价酶联免疫分析手工操作检测HBeAg的空白限(LoB)、检出限(LoD)及定量限(LoQ)。方法参照美国临床实验室标准化协会EP-17A文件和有关文献,结合工作实际,将HBeAg的空白样品及系列低浓度样品进行酶联免疫分析手工操作的检测,根据数据的分布规律,采用相应的统计学方法,建立酶联免疫分析手工操作检测HBeAg的LoB、LoD及LoQ并进行评价。结果 HBeAg的LoB为0.131PEI U/mL,LoD为0.350PEI U/mL,LoQ为0.450PEI U/mL。结论厂商声明的LoB得到验证,同时建立了实验室检测HBeAg的LoB、LoD和LoQ,为临床诊断和治疗提供更有价值的信息。 Objective To establish the limit of blank(LoB) ,limit of detection(LoD) and limit of quantitation (LoQ) for the detection of HBeAg by the enzymelinked immunosorbent assay .Methods Referring to CLSI EP‐17A protocol and related literature ,and by combining with our actual works ,the blank sample and a series of low concenration samples were performed the ELISA detection by the manual operation .According to the distribution law of the data ,the corresponding statistical method was adopted to establish the ELISA detection of LoB ,LoD and LoQ of HBeAg by the manual operation .Results LoB of HBeAg measured by the manual operation was 0 .131 PEI U /mL , LoD was 0 .350 PEI U /mL and LoQ was 0 .450 PEI U /mL .Conclusion The LoB of HBeAg stated by the manufacturer is verified .At the same time ,LoB ,LoD and LoQ of HBeAg detected by our laboratory are established ,which provide more valuable information for the clinical diagnosis and therapy .
出处 《检验医学与临床》 CAS 2015年第18期2656-2658,共3页 Laboratory Medicine and Clinic
基金 卫生部医药卫生科技发展研究中心资助项目(28-1-45)
关键词 乙型肝炎E抗原 酶联免疫吸附试验 空白限 检出限 定量限 HBeAg enzyme-linked immunosorbent assay limit of blank limit of detection limit of quantitation
  • 相关文献

参考文献11

二级参考文献58

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 3高月亭,陈涛,刘汉欣,刘忠民,李宁,肖洪广.应用EP10-A初步评价XI-921型电解质分析仪[J].现代临床医学生物工程学杂志,2006,12(6):507-509. 被引量:4
  • 4European Association for the Study of the Liver.EASL clinical practice guidelines; management of chronic hepatitis B.J Hepatol,2009,50:227-242. 被引量:1
  • 5Lok AS,McMahon BJ.Chronic hepatitis B:update 2009.Hepatology,2009,50:661-662. 被引量:1
  • 6Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat,2003,10:298-305. 被引量:1
  • 7Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med,2005,352:2682-2695. 被引量:1
  • 8Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2004,351:1206-1217. 被引量:1
  • 9Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudinefor HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129. 被引量:1
  • 10Lau GKK,Piratvisuth T,Luo KX,et al.Durability of response and occurrence of late response to peginterferon alpha-2a (40KD)[PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B.J Hepatology,2006,44(Suppl 2),S23-24. 被引量:1

共引文献138

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部